Epicrispr Biotechnologies

Executive Summary

Epicrispr Biotechnologies is an early-stage biotechnology company pioneering epigenetic editing to precisely control gene expression without altering DNA sequence. Founded in 2018 and based in Cambridge, MA, the company aims to address complex diseases through dynamic regulation of gene activity. While still in preclinical stages, Epicrispr's platform has potential applications in oncology, genetic disorders, and chronic diseases. The company has yet to disclose specific pipeline programs or funding details, but its approach represents a cutting-edge area of gene therapy. Key risks include technical challenges in delivering epigenetic editors in vivo and competition from established CRISPR players. However, the ability to reversibly modulate gene expression offers advantages over conventional gene editing, particularly for diseases requiring temporary or graded control.

Upcoming Catalysts (preview)

• Q3 2026Publication of preclinical proof-of-concept data in a major disease model60% success
• Q4 2026Series A funding round announcement to support lead program advancement70% success
• Q2 2027Partnership or collaboration with a larger biopharma for platform development40% success